14 March 2024
14 March 2024
The Phase III trial will evaluate the effect of AstraZeneca’s triple-combination inhaled therapy Breztri on the reduction of cardiopulmonary events in COPD.
Empros Pharma is hopeful that if approved, its combination therapy could become a second-line therapy for obesity.
The company expects to release comprehensive data from the trial in the second half of this year.
The two-phase ArMaDa trial aims to evaluate the safety of OCU410 in GA patients.
ION224 was found to be safe and well-tolerated without any treatment-associated serious adverse events.
The treatment with mezagitamab was generally safe and well-tolerated across all cohorts in the trial.
The device, currently being tested in a trial for rheumatoid arthritis, will next enter a trial for multiple sclerosis patients.
Exact Sciences submitted a pre-market approval application for the device to the FDA in December 2023.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
